Related Experiment Videos
Epidermal cyclic GMP is increased in psoriasis lesions
The Journal of Investigative Dermatology
|January 1, 1981
Summary
Cyclic guanosine monophosphate (cGMP) levels are significantly elevated in the lesional epidermis of psoriasis patients compared to normal skin. This finding highlights potential roles for cGMP in psoriatic skin disease.
Area of Science:
- Dermatology
- Biochemistry
- Cell Biology
Background:
- Psoriasis is a chronic inflammatory skin condition.
- Alterations in intracellular signaling molecules like cyclic GMP may play a role in psoriasis pathogenesis.
- Accurate measurement of cyclic GMP in skin requires careful sample handling to avoid artifacts.
Purpose of the Study:
- To quantify and compare cyclic GMP levels in the epidermis of normal subjects and psoriatic patients.
- To investigate the impact of improved radioimmunoassay techniques on cyclic GMP measurements in skin.
Main Methods:
- Utilized a highly sensitive radioimmunoassay for cyclic GMP quantification.
- Implemented technical improvements including in vivo sample freezing and epidermal microdissection.
- Avoided anesthetic injections to prevent ischemia-induced cyclic GMP reduction.
- Ensured epidermal purity by excluding dermal and keratin layer contamination.
Main Results:
- Cyclic GMP levels were approximately 200 fmol/mg tissue dry weight in lesional psoriatic epidermis.
- Normal and uninvolved psoriatic epidermis showed significantly lower cyclic GMP levels (around 70 fmol/mg tissue dry weight).
- Elevated cyclic GMP in lesional epidermis was consistent across measurements normalized to DNA or protein content.
Conclusions:
- Psoriatic lesional epidermis exhibits markedly increased cyclic GMP levels compared to normal epidermis.
- The findings suggest a potential involvement of cyclic GMP dysregulation in the pathophysiology of psoriasis.
- Refined assay methods enhance the reliability of cyclic GMP measurements in dermatological research.